Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Biogen

Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Biogen will report an earnings per share (EPS) of $4.38.

Benzinga

Analyst Ratings for Biogen

Over the past 3 months, 15 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Biogen Earnings Conference Call Is Coming Up, Here's What You Need To Know

Biogen (NASDAQ:BIIB) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Why This Analyst Believes Biogen Is 'Too Good to Ignore'

Biogen Inc’s (NASDAQ: BIIB) base business seems to be worth more than what the Street estimates, and it is possible that investors are not properly valuing royalty streams coming to the company, which contributes 15% of current revenues and 40% of the valuation, according to Wells Fargo.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022

Upgrades

Benzinga

The FDA approved a new drug to treat Alzheimer's, but Medicare won't always pay for it – a doctor explains what researchers know about Biogen's Aduhelm

Medicare finalized its decision to restrict its coverage of Aduhelm, Biogen’s new Alzheimer’s disease drug, on April 8, 2022.

The Conversation

Medicare’s strict Alzheimer’s policy raises ante for drugmakers

The U.S. Medicare program’s decision to tightly limit coverage for the first drug meant to slow the course of Alzheimer’s disease has raised the stakes for companies trying to make the next one.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

Commentary: Medicare is cleaning up the FDA’s mess on Biogen’s Alzheimer’s drug

Medicare has decided once and for all not to pay for Biogen’s new Alzheimer’s drug Aduhelm unless patients are enrolled in a clinical study.

Tribune News Service

Morning Brief: Top Stories Dominating Financial Media on Friday, April 8

Reuters

Benzinga

Biogen's Alzheimer's Drug Aduhelm Medicare Coverage Restricted To Just Clinical Trials, CMS Finalizes

Centers for Medicare and Medicaid Services (CMS) finalized its decision to restrict coverage for Biogen Inc's (NASDAQ:&

Benzinga

Medicare's limits on Aduhelm coverage sparks questions about future drugs

The Biden administration announced Medicare will cover Aduhelm, but will require patients to be enrolled in a clinical trial in order to access the drug.

Axios

Medicare weighs premium cut after limiting Alzheimer's drug

Medicare says it’s considering a cut in enrollee premiums, after officials stuck with an earlier decision to sharply limit coverage for a pricey new Alzheimer’s drug projected to drive up program costs

The Independent UK

Medicare to pay for Biogen’s Alzheimer’s drug only when used in clinical trials

The U.S. Medicare program finalized a plan to only pay for Biogen Inc.’s Alzheimer’s therapy when it’s used in approved clinical trials, while offering a road map to cover drugs that do show clinical benefit in the disease.

Tribune News Service

Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints

Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Wide-Moat Stocks That Look Cheap: Biogen, Medtronic, and Bristol-Myers Squibb

: Major stock indices appear heading for weekly gains with the Fed’s first interest rate hike digested easily by investors. However, the market is expected to remain under pressure in the near term. So, because wide-moat companies generally do well in these market conditions, we think cheap wide-moat stocks Bristol-Myers…

Tribune News Service

Biogen lays out awaited Alzheimer’s drug data in obscure journal

Biogen Inc. on Wednesday published the full efficacy results from two late-stage studies of its Alzheimer’s disease drug Aduhelm in a lesser-known medical journal, nine months after U.S. regulators cleared the treatment.

Benzinga

Biogen Shares Aduhelm Data In Alzheimer's Disease At 128 Weeks

Biogen Inc (NASDAQ:BIIB) has announced new data from the long-term extension phase of the Phase 3 trials of Aduhelm (aducanumab-avwa) in Alzheimer's disease. The data exhibited that after nearly two and a half years of treatment (128 weeks) with Aduhelm, patients continued to experience significant reductions in two key Alzheimer's disease pathologies, amyloid-beta…

Benzinga

Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact

Eisai Co Ltd (OTC:ESALY) is giving up its right to share in profits from Aduhelm (aducanumab-avwa), which was developed in partnership with Biogen Inc (NASDAQ:BIIB). Biogen and Eisai have amended their agreement to give Biogen full authority to make regulatory and sales decisions regarding Aduhelm. From 2023, Eisai will receive royalties starting at 2% of…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Biogen Posts New Updates Across its Spinraza SMA Research Program

Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and NURTURE studies.

Benzinga

Why This Analyst Sees Roughly 20% Upside In This Large-Cap Biopharma

Biogen Inc (NASDAQ: BIIB) shares are now trading notably off their all-time high of $468.55 hit on June 7, achieved on the back of Aduhel

Benzinga

Expert Ratings For Biogen

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:

Tribune News Service

Inside the tactical tug of war over the controversial Alzheimer’s drug

The drug industry, patient advocates and congressional Republicans have all attacked federal officials’ decision to decline routine Medicare coverage for a controversial Alzheimer’s drug. They’ve gone as far as to accuse them of tacit racism, ageism and discrimination against the disabled — and hinted at a lawsuit — over the…

Tribune News Service

Patients’ groups, progressives square off over Medicare Alzheimer’s decision

WASHINGTON — Advocates on both sides of a debate over dramatically restricting Medicare’s coverage of an expensive and controversial Alzheimer’s treatment are waging competing campaigns to influence a final decision in April.

Roll Call

Patients' groups, progressives square off over Medicare Alzheimer's decision - Roll Call

Competing campaigns look to influence the debate over dramatically restricting coverage of a controversial treatment drug Aduhelm.

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

United States

403,625 stories

50 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.